Editas Medicine (EDIT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

EDIT Editas Medicine

Watchlist

2.900
-0.120-3.97%

Close Oct 31 16:00 ET

2.900
0.0000.00%

Post 20:01 ET

239.18MMarket Cap-1244P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock?
Yahoo FinanceOct 31 03:55 ET
Editas Medicine: Strategic Shift Towards In Vivo Technologies and Long-term Growth Potential
TipRanksOct 25 05:15 ET
Wells Fargo Maintains Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $9
Moomoo NewsOct 24 06:31 ET · Ratings
Truist Financial Maintains Editas Medicine(EDIT.US) With Buy Rating
Moomoo NewsOct 24 06:31 ET · Ratings
Oppenheimer Maintains Editas Medicine(EDIT.US) With Hold Rating, Cuts Target Price to $10
Moomoo NewsOct 24 06:31 ET · Ratings
US stock market unusual movement | Wells Fargo & Co lowered the target price to $9, Editas Medicine (EDIT.US) fell more than 2%.
On Wednesday, editas medicine (EDIT.US) saw a decline in stock price, down 2.58% to $3.205 as of press time.
Zhitong FinanceOct 23 10:39 ET

Comments

Trytosaveabit

Oct 22 06:22

$Editas Medicine (EDIT.US)$ Editas Medicine Announced In Vivo Preclinical Proof Of Concept Data Of Hematopoietic Stem And Progenitor Cell Editing And Fetal Hemoglobin Induction In Humanized Mice Engrafted With Human Hematopoietic Stem Cells And Lacking Their Own Hematopoietic Cells
Benzinga· 2 mins ago
The Company observed high levels of editing of the HBG1/2 promoter, leveraging clinically validated upregulation strategy, utilizing a novel and Editas-proprietary targeted lipid nanoparticle (tLNP...

Jaguar8

Oct 3 23:44

AH NEWS TODAY

$Editas Medicine (EDIT.US)$
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
Editas Medicine (Nasdaq: EDIT) has announced a $57 million upfront cash payment from DRI Healthcare Trust in exchange for certain future license fees and payments under its Cas9 license agreement with Vertex Pharmaceuticals. This non-dilutive capital will support Editas Medicine's pipeline development and strategic priorities.
The deal includes up to 100% of future ann...

wompwomp1337

Sep 6 06:09

$Editas Medicine (EDIT.US)$ seems like Feng Zhang and his team are making leeway with the ultra selfish gene

frankinglily

May 14 03:38

How does the biotech ecosystem support advancements in personalized medicine & genomics?
• Editing Genes | $CRISPR Therapeutics (CRSP.US)$ , $Intellia Therapeutics (NTLA.US)$ , $Beam Therapeutics (BEAM.US)$ , $Verve Therapeutics (VERV.US)$ , $Editas Medicine (EDIT.US)$
• Creating Therapies | $Prime Medicine (PRME.US)$ , $Sana Biotechnology (SANA.US)$
• Building DNA | $Twist Bioscience (TWST.US)$ , $Ginkgo Bioworks (DNA.US)$ , $Pacific Biosciences of California (PACB.US)$ , $Illumina (ILMN.US)$
• Dis...

Jaguar8

May 10 05:01

$Editas Medicine (EDIT.US)$
NEWS
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine demonstrated significant scientific advances in in vivo gene editing technologies, including lipid nanoparticle formulations for efficient delivery and guide RNA modifications to enhance editing potency.
The efficacy of AsCas12a nuclease in vivo was demonstrated by Editas Medicine, sho...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

Concept

Gene Editing

Intraday-0.25%

EDIT Editas Medicine

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target